Oncology Drugs

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

OSE Immunotherapeutics confirms Marc Le Bozec as CEO, betting on his turnaround expertise to navigate market pressures and commercialize its key therapies.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

A new UK facility, backed by government funds, will be the only one of its kind, aiming to accelerate drug development and boost domestic life sciences.

A new report from the nation's largest eye care provider boasts stellar results. We dig into the data, the industry trends, and what it means for patients.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.